Which has better earnings and valuation, RLMD or VANI?

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Vivani Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Relmada Therapeutics N/A N/A -$57.38M -$0.90 N/A Vivani Medical N/A N/A -$26.61M -$0.35 N/A

Is RLMD or VANI more profitable?

Relmada Therapeutics' return on equity of -47.52% beat Vivani Medical's return on equity. Company Net Margins Return on Equity Return on Assets Relmada Therapeutics N/A -47.52% -43.97% Vivani Medical N/A -191.05% -70.91%

Does the media prefer RLMD or VANI?

In the previous week, Relmada Therapeutics had 5 more articles in the media than Vivani Medical. MarketBeat recorded 7 mentions for Relmada Therapeutics and 2 mentions for Vivani Medical. Relmada Therapeutics' average media sentiment score of 0.60 beat Vivani Medical's score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Vivani Medical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend VANI or CGC?

Vivani Medical presently has a consensus target price of $3.75, indicating a potential upside of 169.78%. Given Vivani Medical's stronger consensus rating and higher probable upside, equities analysts clearly believe Vivani Medical is more favorable than Canopy Growth. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivani Medical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Canopy Growth 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Is BIOA or VANI more profitable?

Vivani Medical has a net margin of 0.00% compared to BioAge Labs' net margin of -912.26%. BioAge Labs' return on equity of -28.99% beat Vivani Medical's return on equity. Company Net Margins Return on Equity Return on Assets BioAge Labs -912.26% -28.99% -27.09% Vivani Medical N/A -191.05% -70.91%

Does the media prefer BIOA or VANI?

In the previous week, BioAge Labs had 3 more articles in the media than Vivani Medical. MarketBeat recorded 5 mentions for BioAge Labs and 2 mentions for Vivani Medical. BioAge Labs' average media sentiment score of 1.39 beat Vivani Medical's score of 0.00 indicating that BioAge Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vivani Medical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, VANI or AVIR?

Vivani Medical is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vivani Medical N/A N/A -$26.61M -$0.35 N/A Atea Pharmaceuticals N/A N/A -$158.35M -$2.08 N/A

Is VANI or AVIR more profitable?

Atea Pharmaceuticals' return on equity of -64.25% beat Vivani Medical's return on equity. Company Net Margins Return on Equity Return on Assets Vivani Medical N/A -191.05% -70.91% Atea Pharmaceuticals N/A -64.25% -57.12%

Does the media favor VANI or AVIR?

In the previous week, Vivani Medical and Vivani Medical both had 2 articles in the media. Atea Pharmaceuticals' average media sentiment score of 1.70 beat Vivani Medical's score of 0.00 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vivani Medical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Atea Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Vivani Medical (VANI) Competitors

$1.39 -0.03 (-2.11%)

As of 09/3/2026 04:00 PM Eastern

Compare

VANI vs. COCH, RLMD, CGC, BIOA, and AVIR

Should you buy Vivani Medical stock or one of its competitors? Vivani Medical's main competitors and comparable companies include Envoy Medical (COCH), Relmada Therapeutics (RLMD), Canopy Growth (CGC), BioAge Labs (BIOA), and Atea Pharmaceuticals (AVIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Vivani Medical compare to Envoy Medical?

Envoy Medical (NASDAQ:COCH) and Vivani Medical (NASDAQ:VANI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

Envoy Medical has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market. Comparatively, Vivani Medical has a beta of 2.36, suggesting that its share price is 136% more volatile than the broader market.

In the previous week, Vivani Medical had 2 more articles in the media than Envoy Medical. MarketBeat recorded 2 mentions for Vivani Medical and 0 mentions for Envoy Medical. Envoy Medical's average media sentiment score of 0.00 equaled Vivani Medical'saverage media sentiment score.

Company	Overall Sentiment
Envoy Medical	Neutral
Vivani Medical	Neutral

8.6% of Envoy Medical shares are owned by institutional investors. Comparatively, 6.8% of Vivani Medical shares are owned by institutional investors. 7.1% of Envoy Medical shares are owned by insiders. Comparatively, 53.3% of Vivani Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Vivani Medical has a net margin of 0.00% compared to Envoy Medical's net margin of -11,304.83%. Envoy Medical's return on equity of 0.00% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envoy Medical	-11,304.83%	N/A	-144.13%
Vivani Medical	N/A	-191.05%	-70.91%

Envoy Medical currently has a consensus price target of $2.00, indicating a potential upside of 173.94%. Vivani Medical has a consensus price target of $3.75, indicating a potential upside of 169.78%. Given Envoy Medical's higher probable upside, research analysts clearly believe Envoy Medical is more favorable than Vivani Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envoy Medical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Envoy Medical has higher revenue and earnings than Vivani Medical. Vivani Medical is trading at a lower price-to-earnings ratio than Envoy Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envoy Medical	$240K	234.82	-$23.76M	-$0.76	N/A
Vivani Medical	N/A	N/A	-$26.61M	-$0.35	N/A

Summary

Vivani Medical beats Envoy Medical on 8 of the 14 factors compared between the two stocks.

How does Vivani Medical compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Vivani Medical (NASDAQ:VANI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Relmada Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 174.60%. Vivani Medical has a consensus price target of $3.75, indicating a potential upside of 169.78%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Relmada Therapeutics is more favorable than Vivani Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 6.8% of Vivani Medical shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by insiders. Comparatively, 53.3% of Vivani Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Relmada Therapeutics has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market. Comparatively, Vivani Medical has a beta of 2.36, meaning that its share price is 136% more volatile than the broader market.

In the previous week, Relmada Therapeutics had 5 more articles in the media than Vivani Medical. MarketBeat recorded 7 mentions for Relmada Therapeutics and 2 mentions for Vivani Medical. Relmada Therapeutics' average media sentiment score of 0.60 beat Vivani Medical's score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Vivani Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Relmada Therapeutics' return on equity of -47.52% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-47.52%	-43.97%
Vivani Medical	N/A	-191.05%	-70.91%

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Vivani Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A
Vivani Medical	N/A	N/A	-$26.61M	-$0.35	N/A

Summary

Relmada Therapeutics beats Vivani Medical on 9 of the 14 factors compared between the two stocks.

How does Vivani Medical compare to Canopy Growth?

Vivani Medical (NASDAQ:VANI) and Canopy Growth (NASDAQ:CGC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

Vivani Medical has a beta of 2.36, suggesting that its share price is 136% more volatile than the broader market. Comparatively, Canopy Growth has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

Vivani Medical has higher earnings, but lower revenue than Canopy Growth. Vivani Medical is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivani Medical	N/A	N/A	-$26.61M	-$0.35	N/A
Canopy Growth	$251.01M	1.74	-$190.29M	-$0.45	N/A

In the previous week, Vivani Medical had 2 more articles in the media than Canopy Growth. MarketBeat recorded 2 mentions for Vivani Medical and 0 mentions for Canopy Growth. Canopy Growth's average media sentiment score of 0.58 beat Vivani Medical's score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media.

Company	Overall Sentiment
Vivani Medical	Neutral
Canopy Growth	Positive

Vivani Medical presently has a consensus target price of $3.75, indicating a potential upside of 169.78%. Given Vivani Medical's stronger consensus rating and higher probable upside, equities analysts clearly believe Vivani Medical is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Canopy Growth	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Vivani Medical has a net margin of 0.00% compared to Canopy Growth's net margin of -65.33%. Canopy Growth's return on equity of -21.91% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivani Medical	N/A	-191.05%	-70.91%
Canopy Growth	-65.33%	-21.91%	-14.34%

6.8% of Vivani Medical shares are held by institutional investors. Comparatively, 3.3% of Canopy Growth shares are held by institutional investors. 53.3% of Vivani Medical shares are held by company insiders. Comparatively, 0.4% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Vivani Medical beats Canopy Growth on 9 of the 14 factors compared between the two stocks.

How does Vivani Medical compare to BioAge Labs?

BioAge Labs (NASDAQ:BIOA) and Vivani Medical (NASDAQ:VANI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

Vivani Medical has a net margin of 0.00% compared to BioAge Labs' net margin of -912.26%. BioAge Labs' return on equity of -28.99% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-912.26%	-28.99%	-27.09%
Vivani Medical	N/A	-191.05%	-70.91%

Vivani Medical has lower revenue, but higher earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Vivani Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$8.99M	48.50	-$80.61M	-$2.38	N/A
Vivani Medical	N/A	N/A	-$26.61M	-$0.35	N/A

BioAge Labs has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Vivani Medical has a beta of 2.36, meaning that its stock price is 136% more volatile than the broader market.

BioAge Labs currently has a consensus price target of $36.57, indicating a potential upside of 284.96%. Vivani Medical has a consensus price target of $3.75, indicating a potential upside of 169.78%. Given BioAge Labs' stronger consensus rating and higher probable upside, equities analysts plainly believe BioAge Labs is more favorable than Vivani Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

6.8% of Vivani Medical shares are owned by institutional investors. 17.6% of BioAge Labs shares are owned by insiders. Comparatively, 53.3% of Vivani Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, BioAge Labs had 3 more articles in the media than Vivani Medical. MarketBeat recorded 5 mentions for BioAge Labs and 2 mentions for Vivani Medical. BioAge Labs' average media sentiment score of 1.39 beat Vivani Medical's score of 0.00 indicating that BioAge Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vivani Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BioAge Labs beats Vivani Medical on 8 of the 15 factors compared between the two stocks.

How does Vivani Medical compare to Atea Pharmaceuticals?

Vivani Medical (NASDAQ:VANI) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

6.8% of Vivani Medical shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 53.3% of Vivani Medical shares are held by insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Vivani Medical has a beta of 2.36, suggesting that its stock price is 136% more volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market.

In the previous week, Vivani Medical and Vivani Medical both had 2 articles in the media. Atea Pharmaceuticals' average media sentiment score of 1.70 beat Vivani Medical's score of 0.00 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vivani Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atea Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Vivani Medical presently has a consensus target price of $3.75, indicating a potential upside of 169.78%. Atea Pharmaceuticals has a consensus target price of $7.00, indicating a potential upside of 20.27%. Given Vivani Medical's higher possible upside, research analysts clearly believe Vivani Medical is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Atea Pharmaceuticals' return on equity of -64.25% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivani Medical	N/A	-191.05%	-70.91%
Atea Pharmaceuticals	N/A	-64.25%	-57.12%

Vivani Medical is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivani Medical	N/A	N/A	-$26.61M	-$0.35	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A

Summary

Atea Pharmaceuticals beats Vivani Medical on 7 of the 13 factors compared between the two stocks.

Get Vivani Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VANI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VANI vs. The Competition

Export

Metric	Vivani Medical	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$128.09M	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-3.97	787.27	273.29	25.38
Price / Sales	N/A	753.79	613.45	92.55
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	6.62	12.33	12.89	6.14
Net Income	-$26.61M	$2.82B	$3.47B	$349.01M
7 Day Performance	-2.11%	2.59%	0.60%	-0.27%
1 Month Performance	-0.71%	6.95%	5.73%	0.68%
1 Year Performance	1.46%	9.45%	25.35%	14.84%

Vivani Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VANI Vivani Medical	2.6389 of 5 stars	$1.39 -2.1%	$3.75 +169.8%	+19.8%	$128.09M	N/A	N/A	20	News Coverage
COCH Envoy Medical	1.8793 of 5 stars	$0.73 -0.7%	$2.00 +173.6%	-45.1%	$56.81M	$240K	N/A	34	Gap Up
RLMD Relmada Therapeutics	2.2724 of 5 stars	$4.52 -0.7%	$12.00 +165.5%	+197.3%	$485.35M	N/A	N/A	10
CGC Canopy Growth	1.0171 of 5 stars	$1.01 -2.4%	N/A	-30.5%	$465.02M	$251.01M	N/A	1,128
BIOA BioAge Labs	3.8679 of 5 stars	$10.08 +2.4%	$36.57 +262.8%	+100.4%	$451.63M	$8.99M	N/A	N/A	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VANI) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vivani Medical (VANI) Competitors

VANI vs. COCH, RLMD, CGC, BIOA, and AVIR

How does Vivani Medical compare to Envoy Medical?

Summary

How does Vivani Medical compare to Relmada Therapeutics?

Summary

How does Vivani Medical compare to Canopy Growth?

Summary

How does Vivani Medical compare to BioAge Labs?

Summary

How does Vivani Medical compare to Atea Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VANI vs. The Competition

Vivani Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vivani Medical (VANI) Competitors

VANI vs. COCH, RLMD, CGC, BIOA, and AVIR

How does Vivani Medical compare to Envoy Medical?

Which has more risk & volatility, COCH or VANI?

Does the media prefer COCH or VANI?

Do institutionals & insiders believe in COCH or VANI?

Is COCH or VANI more profitable?

Do analysts recommend COCH or VANI?

Which has stronger earnings and valuation, COCH or VANI?

Summary

How does Vivani Medical compare to Relmada Therapeutics?

Do analysts rate RLMD or VANI?

Do institutionals & insiders hold more shares of RLMD or VANI?

Which has more volatility & risk, RLMD or VANI?

Does the media prefer RLMD or VANI?

Is RLMD or VANI more profitable?

Which has better earnings and valuation, RLMD or VANI?

Summary

How does Vivani Medical compare to Canopy Growth?

Which has more risk & volatility, VANI or CGC?

Which has preferable earnings and valuation, VANI or CGC?

Does the media favor VANI or CGC?

Do analysts recommend VANI or CGC?

Is VANI or CGC more profitable?

Do insiders & institutionals believe in VANI or CGC?

Summary

How does Vivani Medical compare to BioAge Labs?

Is BIOA or VANI more profitable?

Which has preferable earnings & valuation, BIOA or VANI?

Which has more volatility and risk, BIOA or VANI?

Do analysts rate BIOA or VANI?

Do insiders and institutionals believe in BIOA or VANI?

Does the media prefer BIOA or VANI?

Summary

How does Vivani Medical compare to Atea Pharmaceuticals?

Do institutionals & insiders believe in VANI or AVIR?

Which has more risk and volatility, VANI or AVIR?

Does the media favor VANI or AVIR?

Do analysts prefer VANI or AVIR?

Is VANI or AVIR more profitable?

Which has better earnings & valuation, VANI or AVIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VANI vs. The Competition

Vivani Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools